LOXL3

Across TCGA pan-cancer cohorts, LOXL3 Mutation is linked to patient survival in 10 of 34 cancer types, making it a survival-associated LOXL3 data layer compared with 23 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher LOXL3 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated LOXL3 expression acts as an unfavorable survival marker.

OV, CESC, and KIRC are the cancer types where LOXL3 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
OV	OS	Median	II,III,IV	0.010	0.844	<.001	36	view →
CESC	OS	Median	II,III,IV	0.068	0.830	<.001	24	view →
KIRC	OS	Median	All	0.182	0.805	.003	15	view →
HNSC	OS	Median	II,III,IV	0.174	0.711	.016	9	view →
ACC	DFS	Median	All	0.089	0.666	.017	6	view →
SCLC	DFS	Median	All	0.192	0.793	.017	6	view →
STAD	OS	Median	III,IV	0.184	0.641	.011	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
LIHC	DFS	Median	II,III,IV	0.072	0.429	.001	6	view →
SKCM	OS	Median	III,IV	0.216	0.721	.001	3	view →

Pink = unfavorable, green = favorable. Showing the 10 strongest of 10 lineages.

LOXL3–OV (OS)

Open the OV breakdown →